Research records indexed for GLP-1

This page carries 12 of the 25,817 records that the literature query returned for GLP-1, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 25,805 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is GLP-1.

Indexed records

Records retrieved for GLP-1, newest first
RecordYearStudy typeModeln as statedWhat it reported
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy pmid:392893392024Research Support, Non-U.S. Gov't, review-articleotherNot statedIndexed as research support, non-u.s. gov't, review-article. study model from MeSH "Animals" with no rodent species heading. subject headings: Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor.
Glucagon-like peptide 1 (GLP-1) pmid:317671822019Research Support, Non-U.S. Gov't, review-articleotherNot statedIndexed as research support, non-u.s. gov't, review-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetes Mellitus, Type 2; Obesity; Gastric Inhibitory Polypeptide; Insulin; Glucose.
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials pmid:314220622019Meta-Analysis, Research Support, Non-U.S. Gov'totherNot statedIndexed as meta-analysis, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Randomized Controlled Trials As Topic.
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 pmid:296176412018Research Support, Non-U.S. Gov't, ReviewrodentNot statedIndexed as research support, non-u.s. gov't, review. study model from MeSH "Mice". subject headings: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Weight Gain; Insulin.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial pmid:302937702018Clinical Trial, Phase II, Multicenter Studyhuman trialNot statedIndexed as clinical trial, phase ii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Weight Loss; Gastric Inhibitory Polypeptide; Blood Glucose; Recombinant Fusion Proteins.
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide pmid:263080952015Journal ArticlerodentNot statedIndexed as journal article. study model from MeSH "Rats, Sprague-Dawley". subject headings: Cell Line; Swine; Swine, Miniature; Mice, Obese; Rats, Sprague-Dawley.
The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents pmid:251097812015Research Support, Non-U.S. Gov't, research-articlerodentNot statedIndexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Colon; Mice, Inbred C57BL; Rats, Wistar; Propionates; Gastrointestinal Hormones.
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss pmid:252029802014Research Support, Non-U.S. Gov't, research-articlerodentNot statedIndexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Transgenic". subject headings: Hypothalamus; Paraventricular Hypothalamic Nucleus; Neurons; Vagus Nerve; Mice, Transgenic.
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody pmid:244677462014Journal ArticlerodentNot statedIndexed as journal article. study model from MeSH "Mice, Inbred C57bl". subject headings: Duodenum; Cell Line; Venoms; Mice, Inbred C57BL; Mice, Knockout.
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2 pmid:221906482012Research Support, Non-U.S. Gov't, research-articlerodentNot statedIndexed as research support, non-u.s. gov't, research-article. study model from MeSH "Mice, Inbred C57bl". subject headings: Colon; Mice, Inbred C57BL; Calcium; GTP-Binding Protein Alpha Subunits, Gi-Go; Fatty Acids, Volatile.
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus pmid:229453602012ReviewotherNot statedIndexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Venoms; Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Hypoglycemic Agents.
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials pmid:222364112012Meta-Analysis, research-articleotherNot statedIndexed as meta-analysis, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Venoms; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Peptides.

Where this page sits

Compound page: GLP-1. Class: Incretin receptor agonists.

Retrieved 2026-10-12.

Sources

  1. PubChem Compound Summary for CID 16133831, Glucagon-Like Peptide 1. PubChem, National Library of Medicine (2026). pubchem:16133831
  2. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:glp-1
  3. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (London, England) (1987). pmid:2890903
  4. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of clinical investigation (1993). pmid:8423228
  5. The physiology of glucagon-like peptide 1. Physiological reviews (2007). pmid:17928588
  6. Glucagon-like peptide 1 (GLP-1). Mol Metab (2019). pmid:31767182
  7. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996). pmid:8538742
  8. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2012). pmid:22190648
  9. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006). pmid:17098089
  10. Biology of incretins: GLP-1 and GIP. Gastroenterology (2007). pmid:17498508
  11. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism (2018). pmid:29617641
  12. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The lancet. Diabetes & endocrinology (2019). pmid:31422062
  13. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The lancet. Diabetes & endocrinology (2021). pmid:34425083

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources